Breast cancer’s resistance to treatment is a major hurdle in improving patient outcomes. A recent study explores how tumor angiogenesis–the formation of abnormal blood vessels in tumors–plays a pivotal role in fostering drug resistance. The research highlights how these blood vessels hinder drug delivery and create a hostile tumor environment, reducing the effectiveness of therapies. It also investigates the potential of anti-angiogenic treatments to normalize these vessels, enhancing drug efficacy and offering new hope for patients.
